$3.15 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 90 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 51.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FIXX | Sell | HOMOLOGY MEDICINES INC | $62,740,000 | -42.2% | 4,037,305 | -23.0% | 1.99% | -42.5% |
| RYTM | Sell | RHYTHM PHARMACEUTICALS INC | $46,140,000 | -53.1% | 3,031,565 | -29.3% | 1.46% | -53.4% |
| ALEC | Sell | ALECTOR INC | $41,962,000 | +17.3% | 1,738,997 | -16.3% | 1.33% | +16.6% |
| FATE | Sell | FATE THERAPEUTICS INC | $35,913,000 | -8.4% | 1,616,993 | -19.3% | 1.14% | -8.8% |
| XENT | Sell | INTERSECT ENT INC | $32,685,000 | -53.1% | 2,758,267 | -1.4% | 1.04% | -53.3% |
| XLRN | Sell | ACCELERON PHARMA INC | $30,825,000 | -57.6% | 343,000 | -75.0% | 0.98% | -57.8% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $26,782,000 | -40.8% | 457,968 | -18.9% | 0.85% | -41.1% |
| TNDM | Sell | TANDEM DIABETES CARE INC | $26,568,000 | -67.3% | 412,867 | -69.7% | 0.84% | -67.4% |
| RCKT | Sell | ROCKET PHARMACEUTICALS INC | $23,399,000 | -52.5% | 1,677,367 | -22.5% | 0.74% | -52.7% |
| ARGX | Sell | ARGENX SEsponsored adr | $19,994,000 | -32.3% | 151,779 | -17.5% | 0.64% | -32.6% |
| ARDX | Sell | ARDELYX INC | $17,527,000 | -66.7% | 3,083,000 | -56.0% | 0.56% | -66.8% |
| AVRO | Sell | AVROBIO INC | $17,503,000 | -25.4% | 1,124,879 | -3.4% | 0.56% | -25.8% |
| FREQ | Sell | FREQUENCY THERAPEUTICS INC | $16,843,000 | -32.3% | 945,718 | -33.3% | 0.54% | -32.5% |
| MYOK | Sell | MYOKARDIA INC | $16,240,000 | -71.8% | 346,409 | -56.1% | 0.52% | -71.9% |
| FTSV | Sell | FORTY SEVEN INC | $14,826,000 | -15.8% | 155,380 | -65.2% | 0.47% | -16.0% |
| CABA | Sell | CABALETTA BIO INC | $9,375,000 | -58.8% | 1,284,313 | -21.1% | 0.30% | -59.0% |
| BCRX | Sell | BIOCRYST PHARMACEUTICALS INC | $9,306,000 | -57.7% | 4,652,926 | -27.0% | 0.30% | -58.0% |
| KMPH | Sell | KEMPHARM INC | $94,000 | -52.0% | 418,613 | -19.1% | 0.00% | -50.0% |
| PRTO | Exit | PROTEON THERAPEUTICS INC | $0 | – | -2,029,000 | -100.0% | -0.03% | – |
| ALPN | Exit | ALPINE IMMUNE SCIENCES INC | $0 | – | -248,992 | -100.0% | -0.03% | – |
| AERI | Exit | AERIE PHARMACEUTICALS INCput | $0 | – | -103,800 | -100.0% | -0.08% | – |
| INGN | Exit | INOGEN INC | $0 | – | -37,016 | -100.0% | -0.08% | – |
| SWAV | Exit | SHOCKWAVE MED INC | $0 | – | -70,000 | -100.0% | -0.10% | – |
| Exit | INTERCEPT PHARMACEUTICALS INnote 2.000% 5/1 | $0 | – | -3,500,000 | -100.0% | -0.15% | – | |
| XFOR | Exit | X4 PHARMACEUTICALS INC | $0 | – | -449,437 | -100.0% | -0.15% | – |
| TXMD | Exit | THERAPEUTICSMD INC COM STK | $0 | – | -2,250,000 | -100.0% | -0.17% | – |
| ATRC | Exit | ATRICURE INC | $0 | – | -292,777 | -100.0% | -0.30% | – |
| KIDS | Exit | ORTHOPEDIATRICS CORP | $0 | – | -225,000 | -100.0% | -0.34% | – |
| KOD | Exit | KODIAK SCIENCES INC | $0 | – | -200,000 | -100.0% | -0.46% | – |
| RVNC | Exit | REVANCE THERAPEUTICS INC | $0 | – | -900,000 | -100.0% | -0.47% | – |
| ADUS | Exit | ADDUS HOMECARE CORP | $0 | – | -197,915 | -100.0% | -0.61% | – |
| EHTH | Exit | EHEALTH INC | $0 | – | -204,000 | -100.0% | -0.62% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -251,000 | -100.0% | -0.64% | – |
| BOLD | Exit | AUDENTES THERAPEUTICS INC | $0 | – | -493,901 | -100.0% | -0.94% | – |
| HUM | Exit | HUMANA INC | $0 | – | -82,000 | -100.0% | -0.96% | – |
| Exit | DEXCOM INCnote 0.750%12/0 | $0 | – | -34,000,000 | -100.0% | -1.61% | – | |
| RARX | Exit | RA PHARMACEUTICALS INC | $0 | – | -1,519,718 | -100.0% | -2.28% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
| 13F-HR | 2023-11-14 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.